Ftse Mib
37.675,40
-1,44%
DAX
22.328,77
-1,23%
S&P 500
5.583,30
-0,56%
NASDAQ
17.553,66
0,49%
Bitcoin
83.043,93
5,82%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Iterum Therapeutics PLC (ITRM) Iterum Therapeutics PLC (ITRM) Notizie

Iterum Therapeutics PLC

ITRM
1,36
0,05 (3,82%)
Ultimo aggiornamento: 20:34:22
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/3/202513:35EDGAR2Form 8-K - Current report
20/2/202506:15EDGAR2Form EFFECT - Notice of Effectiveness
14/2/202522:49EDGAR2Form 8-K - Current report
07/2/202522:33EDGAR2Form S-3 - Registration statement under Securities Act of..
07/2/202513:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/2/202513:15EDGAR2Form 8-K - Current report
07/2/202513:00GLOBEIterum Therapeutics Reports Fourth Quarter and Full Year..
31/1/202514:00GLOBEIterum Therapeutics to Report Fourth Quarter and Full Year..
11/12/202412:30EDGAR2Form 8-K - Current report
10/12/202413:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/11/202415:15EDGAR2Form 8-K - Current report
21/11/202414:30GLOBEIterum Therapeutics Regains Full Nasdaq Compliance
14/11/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202413:15EDGAR2Form 8-K - Current report
14/11/202413:00GLOBEIterum Therapeutics Reports Third Quarter 2024 Financial..
11/11/202414:00GLOBEIterum Therapeutics to Report Third Quarter 2024 Financial..
01/11/202422:10EDGAR2Form 8-K - Current report
30/10/202411:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/10/202411:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/10/202410:00PRNUSIterum Therapeutics to Host Morning Conference Call on U.S...
25/10/202417:20EDGAR2Form 8-K - Current report
25/10/202417:03GLOBEIterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™..
15/10/202414:00EDGAR2Form 8-K - Current report
11/10/202422:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/10/202414:30GLOBEIterum Therapeutics to Present Data at IDWeek 2024
09/10/202423:00GLOBEIterum Therapeutics to Participate at the 2024 Maxim..
08/10/202415:15EDGAR2Form 8-K - Current report
04/10/202423:20EDGAR2Form 8-K - Current report
30/9/202422:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/9/202413:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/9/202415:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/9/202414:59EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/9/202412:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/9/202422:50EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/9/202413:00GLOBEIterum Therapeutics Provides Update on FDA Advisory..
09/9/202412:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/9/202422:30GLOBEIterum Therapeutics to Present at the 26th Annual H.C...
14/8/202422:15EDGAR2Form DEF 14A - Other definitive proxy statements
14/8/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202413:15EDGAR2Form 8-K - Current report
14/8/202413:00GLOBEIterum Therapeutics Reports Second Quarter 2024 Financial..
09/8/202423:28EDGAR2Form POS AM - Post-Effective amendments for registration..
07/8/202422:30GLOBEIterum Therapeutics to Report Second Quarter 2024 Financial..
06/8/202423:30GLOBEIterum Therapeutics Announces Expiration and Results of..
06/8/202423:25EDGAR2Form 8-K - Current report
02/8/202422:30EDGAR2Form PRE 14A - Other preliminary proxy statements
02/8/202414:00GLOBEIterum Therapeutics Broadens Patent Estate for Oral..
22/7/202414:30EDGAR2Form 8-K - Current report
22/7/202413:30GLOBEIterum Therapeutics Commences Rights Offering
19/7/202423:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
Apertura: 1,28 Min: 1,27 Max: 1,36
Chiusura: 1,31

La tua Cronologia

NASDAQ
ITRM
Iterum Therapeutics
LSE
PXC
Phoenix Copper
XE
BMW
Bayerische Motoren Werke
CSE
WTER
The Alkaline Water
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci